Correlation Between Loncar Cancer and ALPS Medical

Can any of the company-specific risk be diversified away by investing in both Loncar Cancer and ALPS Medical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Loncar Cancer and ALPS Medical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Loncar Cancer Immunotherapy and ALPS Medical Breakthroughs, you can compare the effects of market volatilities on Loncar Cancer and ALPS Medical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Loncar Cancer with a short position of ALPS Medical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Loncar Cancer and ALPS Medical.

Diversification Opportunities for Loncar Cancer and ALPS Medical

0.8

Correlation Coefficient

Loncar Cancer  ALPS Medical

Very poor diversification

The 3 months correlation between Loncar and ALPS is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Loncar Cancer Immunotherapy and ALPS Medical Breakthroughs in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ALPS Medical Breakth and Loncar Cancer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Loncar Cancer Immunotherapy are associated (or correlated) with ALPS Medical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ALPS Medical Breakth has no effect on the direction of Loncar Cancer i.e., Loncar Cancer and ALPS Medical go up and down completely randomly.

Pair Corralation between Loncar Cancer and ALPS Medical

Given the investment horizon of 90 days Loncar Cancer Immunotherapy is expected to under-perform the ALPS Medical. In addition to that, Loncar Cancer is 1.36 times more volatile than ALPS Medical Breakthroughs. It trades about -0.13 of its total potential returns per unit of risk. ALPS Medical Breakthroughs is currently generating about -0.09 per unit of volatility. If you would invest  3,308  in ALPS Medical Breakthroughs on December 28, 2024 and sell it today you would lose (318.00) from holding ALPS Medical Breakthroughs or give up 9.61% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Loncar Cancer Immunotherapy  vs.  ALPS Medical Breakthroughs

Loncar Cancer Immuno

Risk-Adjusted Performance

Very Weak

Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors.

ALPS Medical Breakth

Risk-Adjusted Performance

Very Weak

Over the last 90 days ALPS Medical Breakthroughs has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Etf's forward indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the ETF investors.

Pair Trading with Loncar Cancer and ALPS Medical

The main advantage of trading using opposite Loncar Cancer and ALPS Medical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Loncar Cancer position performs unexpectedly, ALPS Medical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALPS Medical will offset losses from the drop in ALPS Medical's long position.

The idea behind Loncar Cancer Immunotherapy and ALPS Medical Breakthroughs pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.